Navigation Links
Neurocrine Biosciences Reports Third Quarter 2013 Results
Date:10/29/2013

s in 280 women with heavy uterine bleeding due to uterine fibroids.

VMAT2 UpdateThe Company has completed enrollment in Kinect 2, a Phase IIb study of its VMAT2 inhibitor, NBI-98854. This study is a 90 subject, placebo-controlled, double-blind, parallel-design, multiple-dose, six-week study assessing NBI-98854 in doses up to 75mg once-a-day against placebo in tardive dyskinesia patients with underlying mood disorders, schizophrenia and schizoaffective disorders, and gastrointestinal disorders. The primary endpoint is the Abnormal Involuntary Movement Scale (AIMS) at the end of the six weeks of dosing. The video AIMS will be scored by blinded central reviewers who are movement disorder neurologists. This study recently completed screening and randomization of subjects, and top-line data from this study is expected in December of 2013.

In 2014, the Company intends to initiate another clinical study of NBI-98854 in tardive dyskinesia patients. This study is currently in the design phase, and the results of the Kinect and Kinect 2 Studies will serve to inform the ultimate design of this clinical trial. The primary endpoint in this study will be the AIMS assessed by blinded central reviewers who are movement disorder neurologists.

The Company is currently completing two Phase I studies for NBI-98854 assessing drug-drug interactions as well as the impact of hepatic impairment on drug metabolism.

Additionally, the Company is conducting preclinical studies to support the advancement of NBI-98854 into clinical trials for individuals suffering from Tourette's syndrome. Upon successful completion of these preclinical studies, the Company anticipates entering Phase I and Phase II clinical studies in 2014.

Conference Call and Webcast Today at 5:00PM Eastern Time
Neurocrine will hold a live conference call and webcast today at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time). Participants can access the live conference call by dialing 866-952
'/>"/>

SOURCE Neurocrine Biosciences, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Neurocrine Biosciences Reports Second Quarter 2013 Results
2. Neurocrine Biosciences Announces Conference Call And Webcast To Present Second Quarter 2013 Financial Results
3. Neurocrine Biosciences To Present At The Bank of America Merrill Lynch 2013 Health Care Conference
4. Neurocrine Biosciences Reports Fourth Quarter And Year End 2012 Results
5. Neurocrine Biosciences To Present At The 24th Annual Piper Jaffray Healthcare Conference
6. Neurocrine Biosciences Reports Third Quarter 2012 Results
7. Neurocrine Biosciences Reports Second Quarter 2012 Results
8. Neurocrine Biosciences to Present at The 24th Annual Roth Conference
9. Neurocrine Biosciences to Present at the Citi 2012 Global Health Care Conference
10. Neurocrine Biosciences to Present at the 14th Annual BIO CEO & Investor Conference
11. Proove Biosciences Will Be Exhibiting At The 2013 Common Sense Pain Management Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... September 30, 2014 UFP Technologies, ... specialty packaging has recently introduced a custom insulated ... Pack . The new insulated shipper solves the ... distribution process. UFP Technologies’ BioShell is a universal ... during storage, handling and shipping. The insulated shipper ...
(Date:9/30/2014)... Ontario, Canada (PRWEB) September 30, 2014 Back ... based on 500 square feet. per employee, which included space ... world back then.” says Jeff Howell, partner at Nidea ... advisory firm in Toronto. “By the year 2000, however, ... are now seeing that number come down to 175 to ...
(Date:9/29/2014)... Each year in the US, ... attention. In the military, burn injury is a ... medical care. More than 800 service members sustained ... heal slowly, remain inflamed and often become infected, ... and functionally damaging. While developments in supportive care ...
(Date:9/29/2014)... of the military conflicts in Iraq and Afghanistan, more ... with traumatic brain injury caused by exposure to bomb ... devices, or IEDs. Symptoms of traumatic brain injury can ... nausea, to more severe impairments in memory and cognition. ... has recognized the critical importance and complexity of this ...
Breaking Biology Technology:UFP Technologies Introduces Insulated Shipping Container For Bulk Drug Transportation 2UFP Technologies Introduces Insulated Shipping Container For Bulk Drug Transportation 3ITRA Global Reports on How Companies Are Squeezing More Employees into Less Office Space 2ITRA Global Reports on How Companies Are Squeezing More Employees into Less Office Space 3Faster Healing with Fewer Scars 2Modeling shockwaves through the brain 2Modeling shockwaves through the brain 3Modeling shockwaves through the brain 4
... Pharmaceuticals,Inc. (NYSE: BRL ) today confirmed that ... of the patents listed by Amgen Inc. in,connection ... 90mg., Barr,s Abbreviated New Drug Application (ANDA) ... product was received as acceptable,for filing by the ...
... are to be used in clinical trials ... on a path to finally cure diabetes, ... recently declared its commitment to support Spring Point,Project, a Minnesota non-profit ... of islet tissue for,diabetes care., (Logo: http://www.newscom.com/cgi-bin/prnh/20071214/CLF057LOGO-b ), ...
... as an Antipsychotic Agent with Less Potential for ... Weight Gain and Metabolic Risks, SAN DIEGO, July ... announced that the United States Patent and,Trademark Office (USPTO) ... would provide broad coverage for a pharmaceutical,composition of zonisamide ...
Cached Biology Technology:Barr Confirms Patent Challenge of Sensipar(R) Tablets, 30mg, 60mg and 90mg 2Barr Confirms Patent Challenge of Sensipar(R) Tablets, 30mg, 60mg and 90mg 3Spring Point Project Gains Support of Lions Clubs 2Spring Point Project Gains Support of Lions Clubs 3OREXIGEN(R) Therapeutics Receives Notice of Allowance for U.S. Patent Covering the Composition of Matter in OREX-003 2OREXIGEN(R) Therapeutics Receives Notice of Allowance for U.S. Patent Covering the Composition of Matter in OREX-003 3OREXIGEN(R) Therapeutics Receives Notice of Allowance for U.S. Patent Covering the Composition of Matter in OREX-003 4
(Date:9/29/2014)... order to support the world,s needs to make ... more, new and more efficient catalytic materials and ... including several from Wayne State University, is tackling ... grant from the National Science Foundation. , The ... Multicomponent Materials for Electrocatalytic Cascade Reactions," was to ...
(Date:9/29/2014)... received a five-year, $6 million grant for clinical ... and development of safe and effective treatments for ... the National Institutes of Health, National Institute on ... Medication Development for Cocaine Use Disorder to oversee ... decisions on moving forward with more expensive large-scale ...
(Date:9/29/2014)... review article published online in Behavioral Brain Research ... the brain as a result of chronic alcohol exposure ... , Clinical assessments and research indicate that individuals ... sleep. This can occur when people are actively drinking, ... are abstaining. , "Sleep-wake disturbances can last for ...
Breaking Biology News(10 mins):Wayne State research aims to develop new, more efficient catalytic materials 2New VCU center to target cocaine addiction 2
... 14, 2012 The latest episode in the American ... podcast series describes the development of a new test ... Amid concerns about the threat of terrorist attacks, ... and other nations. One such team has developed a ...
... Irvine researchers have discovered how Salmonella , a bacterium ... in humans, thrives in the digestive tract despite the immune ... explain why Salmonella is difficult to eradicate and ... with Salmonella suffer from diarrhea, fever and abdominal ...
... A parking lot at the edge of the University ... emerging concern for the environment and human health. ... journal Environmental Science & Technology , has found that ... lots throughout the nation, has significant health and ecosystem implications. ...
Cached Biology News:New test could help track down and prosecute terrorists 2UCI-led study uncovers how Salmonella avoids the body's immune response 2UNH research adds to mounting evidence against popular pavement sealcoat 2